These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6839005)

  • 1. Pharmacokinetic evaluation of the blood-to-lymph transfer of cyclosporin A in rats.
    Ueda CT; Lemaire M; Misslin P
    Biopharm Drug Dispos; 1983; 4(1):83-94. PubMed ID: 6839005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apparent dose-dependent oral absorption of cyclosporin A in rats.
    Ueda CT; Lemaire M; Gsell G; Misslin P; Nussbaumer K
    Biopharm Drug Dispos; 1984; 5(2):141-51. PubMed ID: 6743782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal lymphatic absorption of cyclosporin A following oral administration in an olive oil solution in rats.
    Ueda CT; Lemaire M; Gsell G; Nussbaumer K
    Biopharm Drug Dispos; 1983; 4(2):113-24. PubMed ID: 6882880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporin-erythromycin interaction in normal subjects.
    Freeman DJ; Martell R; Carruthers SG; Heinrichs D; Keown PA; Stiller CR
    Br J Clin Pharmacol; 1987 Jun; 23(6):776-8. PubMed ID: 3606938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats.
    Takada K; Usuda H; Oh-Hashi M; Yoshikawa H; Muranishi S; Tanaka H
    J Pharmacobiodyn; 1991 Jan; 14(1):34-42. PubMed ID: 1713626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution kinetics of FK-506, a novel immunosuppressant, after intravenous administration to rats in comparison with cyclosporin A.
    Takada K; Usuda H; Oh-Hashi M
    Biopharm Drug Dispos; 1992 Jul; 13(5):345-55. PubMed ID: 1379839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cyclosporin A after intravenous administration to rats in various disease states.
    Shibata N; Shimakawa H; Minouchi T; Yamaji A
    Biol Pharm Bull; 1993 Nov; 16(11):1130-5. PubMed ID: 8312870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Cyclosporin A on rat thymus: time course analysis by immunoperoxidase technique and flow cytofluorometry.
    Tanaka M; Shinohara K; Fukumoto T; Tanaka H; Kaneko T
    Clin Exp Immunol; 1988 May; 72(2):216-21. PubMed ID: 3044648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue distribution of cyclosporine A in the mouse: a clue to toxicity?
    Belitsky P; Ghose T; Givner M; Rowden G; Pope B
    Clin Nephrol; 1986; 25 Suppl 1():S27-9. PubMed ID: 3708933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of high dose cyclosporin A toxicity by frusemide.
    Whiting PH; Cunningham C; Thomson AW; Simpson JG
    Biochem Pharmacol; 1984 Apr; 33(7):1075-9. PubMed ID: 6712718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporin A serum and blood levels in marrow graft recipients: correlation with administered dose, serum creatinine and graft-versus-host disease.
    Bacigalupo A; Di Giorgio F; Frassoni F; Van Lint MT; Raffo MR; Gogioso L; Viale M; Marmont AM
    Acta Haematol; 1984; 72(3):155-62. PubMed ID: 6438979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue distribution and toxicity of cyclosporin A in the mouse.
    Boland J; Atkinson K; Britton K; Darveniza P; Johnson S; Biggs J
    Pathology; 1984 Apr; 16(2):117-23. PubMed ID: 6462774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotoxicity of cyclosporin A. A lithium clearance and micropuncture study in rats.
    Dieperink H; Leyssac PP; Starklint H; Kemp E
    Eur J Clin Invest; 1986 Feb; 16(1):69-77. PubMed ID: 3084276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interaction between cyclosporin A and nizatidine in Sprague-Dawley rats.
    Filingeri V; Rosati R; Giacomelli R; Famularo G; Iacona A; Cervelli V; Davoli E; Tonietti G; Casciani CU
    Drugs Exp Clin Res; 1990; 16(9):475-9. PubMed ID: 1983111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of administration route on the selective lymphatic delivery of cyclosporin A by lipid-surfactant mixed micelles.
    Takada K; Yoshimura H; Shibata N; Masuda Y; Yoshikawa H; Muranishi S; Yasumura T; Oka T
    J Pharmacobiodyn; 1986 Feb; 9(2):156-60. PubMed ID: 3712214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporin A-induced cholestasis. The mechanism in a rat model.
    Stone BG; Udani M; Sanghvi A; Warty V; Plocki K; Bedetti CD; Van Thiel DH
    Gastroenterology; 1987 Aug; 93(2):344-51. PubMed ID: 3596172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model to account for the blood-to-plasma distribution of cyclosporin A in human blood.
    Shibata N; Minouchi T; Ono T; Shimakawa H
    J Pharmacobiodyn; 1990 Jan; 13(1):20-9. PubMed ID: 2341967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability of cyclosporin A in human serum.
    Smith JM; Hows JM; Gordon-Smith EC
    J Clin Pathol; 1983 Jan; 36(1):41-3. PubMed ID: 6822676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporin reduces renal blood flow through vasoconstriction of arcuate arteries in the hydronephrotic rat model.
    Zimmerhackl LB; Fretschner M; Steinhausen M
    Klin Wochenschr; 1990 Feb; 68(3):166-74. PubMed ID: 2314004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course of cyclosporine and ist motabolites in blood, liver and spleen of naive Lewis rats: comparison with preliminary data obtained in transplanted animals.
    Wacher VJ; Liu T; Roberts JP; Ascher NL; Benet LZ
    Biopharm Drug Dispos; 1995 May; 16(4):303-12. PubMed ID: 7548779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.